Identifying determinants of persistent MRSA bacteremia using mathematical modeling
Fig 7
Pharmacological strategies for persistent and relapsing bacteremia.
(A) Three possible pharmacological strategies, persister killer, persister reverter and persister formation inhibitor, are shown on the schematic diagram of in vivo MRSA model. (B) Doughnut charts show the number of models for resolving bacteremia (RB) without relapse, RB with relapse, persistent bacteremia (PB) without relapse, and PB with relapse by the treatment of three drug candidates in the presence of vancomycin. The pharmacological strengths of persister killer and persister reverter are expressed as a kinetic rate (h-1). During the simulation, persister killer and persister reverter were administrated in conjunction with vancomycin. Persister formation inhibitor was treated from the beginning of the simulation with different initial numbers of persister cells, 1 or 0 cfu/a.u.